Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression

Journal of Clinical Oncology

Volumn 14, Issue 6, 1996, Pages 1778-1786

  Kaempfer, R ^a   Gerez, L ^a   Farbstein, H ^a   Madar, L ^a   Hirschman, O ^a   Nussinovich, R ^a   Shapiro, A ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; MESSENGER RNA;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; DRUG EFFICACY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREGULATION; INTRAVESICAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REMISSION; TREATMENT OUTCOME;

EID: 0029885357     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.6.1778     Document Type: Article

References (37)

1. Silverberg E, Lubera JA: Cancer statistics. CA Cancer J Clin 43:18, 1993
2. Herr HW, Pinsky CM, Whitmore WF Jr, et al: Effect of intravesical bacillus Calmette-Guérin BCG on carcinoma in situ of the bladder. Cancer 51:1323-1326, 1983
3. Lamm DL, Thor DE, Harris SC, et al: Bacillus Calmette-Guérin immunotherapy of superficial bladder cancer. J Urol 142:38-42, 1980
4. Brosman SA: Experience with bacillus Calmette-Guérin in patients with superficial bladder carcinoma. J Urol 128:27-30, 1982
5. Bretton PR, Herr HW, Kimmel M, et al: The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guérin. J Urol 143:710-712, 1990
6. Coplen DE, Marcus MD, Myers JA, et al: Long-term follow-up of patients with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guérin: Analysis of possible predictors of response free of tumor. J Urol 144:652-657, 1990
7. Ratliff TL, Ritchey JK, Yuan JJ, et al: T cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 150:1018-1023, 1993
8. Bubenik J, Kieler J, Tromholt V, et al: Defect in lectin-induced interleukin 2 production by peripheral blood lymphocytes of patients with invasive urinary bladder carcinoma. Immunol Lett 18:115-118, 1988
9. Ikemoto S, Kishimoto T, Wada S, et al: Clinical studies on cell-mediated immunity in patients with urinary bladder carcinoma: Blastogenic response, interleukin-2 production and interferon-gamma production of lymphocytes. Br J Urol 65:333-338, 1990
10. Bohle A, Gerdes J, Ulmer AJ, et al: Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 144:53-58, 1990
11. Bohle A, Busemann E, Gerdes J, et al: Long-term immunobiological effects of intravesical bacillus Calmette-Guérin against bladder carcinoma recurrences. Dev Biol Stand 77:199-209, 1992
12. Boccafoschi C, Montefiore F, Pavesi M, et al: Immunophenotypic characterization of the bladder mucosa infiltrating lymphocytes after intravesical BCG treatment for superficial bladder carcinoma. Eur Urol 21:304-308, 1992
13. De Jong WH, De Boer EC, Van Der Meijden APM, et al: Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guérin. Cancer Immunol Immunother 31:182-186, 1990
14. Fleischman JD, Toossi Z, Ellner JJ, et al: Urinary interleukins in patients receiving intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer. Cancer 64:1447-1454, 1989
15. Bohle A, Nowc C, Ulmer AJ, et al: Elevation of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy. J Urology 144:59-64, 1990
16. Efrat S, Pilo S, Kaempfer R. Kinetics of induction and molecular size of mRNA encoding human interleukin-2 and γ-interferon. Nature 297:236-239, 1982
17. Efrat S, Kaempfer R: Control of biologically active interleukin 2 messenger RNA formation in induced human lymphocytes. Proc Natl Acad Sci USA 81:2601-2605, 1984
18. Lebendiker MA, Tal C, Sayar D, et al: Superinduction of the human gene encoding immune interferon. EMBO J 6:585-589, 1987
19. Efrat S, Zelig S, Yagen B, et al: Superinduction of human interleukin-2 messenger RNA by inhibitors of translation. Biochem Biophys Res Commun 123:842-848, 1984
20. Gerez L, Arad G, Efrat S, et al: Post-transcriptional regulation of human IL-2 gene expression at processing of precursor transcripts. J Biol Chem 270:19569-19575, 1995
21. Shaw J, Meerovitch K, Bleackley RC, et al: Mechanisms regulating the level of IL-2 mRNA in T lymphocytes. J Immunol 140:2245-2248, 1988
22. Shaw J, Meerovitch K, Elliott JF, et al: Induction, suppression and superinduction of lymphokine mRNA in T lymphocytes. Mol Immunol 24:409-419, 1987
23. Kronke M, Leonard J, Depper JM, et al: Sequential expression of genes involved in human T lymphocyte growth and differentiation. J Exp Med 161:1593-1598, 1985
24. Arad G, Ketzinel M, Tal C, et al: Transient expression of human interleukin-2 and interferon-γ genes is regulated by interaction between distinct cell subsets. Cell Immunol 160:240-247, 1995
25. Gerez L, Madar L, Arad G, et al: Aberrant regulation of interleukin-2 but not of interferon-γ gene expression in Down syndrome trisomy 21. Clin Immunol Immunopathol 58:251-266, 1991
26. Gerez L, Madar L, Shkolnik T, et al: Regulation of interleukin-2 and interferon-γ gene expression in renal failure. Kidney Int 40:266-272, 1991.
27. Cheley S, Anderson R: A reproducible microanalytical method for the detection of specific RNA sequences by dot-blot hybridization. Anal Biochem 137:15-19, 1984
28. Sokal RR, Rohlf FJ: Biometry (ed 2). New York, NY, Freeman, 1981
29. Cornell R: Statistical Methods for Cancer Studies. New York, NY, Dekker, 1984
30. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies. J Am Stat Assoc 22:719-748, 1959
31. Harris EK, Albert A: Survivorship Analysis for Clinical Studies. New York, NY, Dekker, 1991
32. Shapiro A, Kadmon D, Catalona WJ, et al: Immunotherapy of superficial bladder cancer. J Urol 128:891-894, 1982
33. Mosmann TR, Cherwinski H, Bond MW, et al: Two types of murine helper T cell clone. 1. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136:2348-2357, 1986
34. Bancroft GJ, Sheehan KC, Schreiber RD, et al: Tumor necrosis factor is involved in the T cell-independent pathway of macrophage activation in scid mice. J Immunol 143:127-123, 1989
35. Bancroft GJ, Schreiber RD, Unanue ER: Natural immunity, a T-cell-independent pathway of macrophage activation, defined in the SCID mouse. Immunol Rev 124:5-24, 1992
36. Mosmann TR, Coffman RL: TH1 and TH2 cell: Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7:145-173, 1989
37. Connor J, Bannerji R, Saito S, et al: Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med 177:1127-1134, 1993